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Based on in vitro data, protein-bound uremic retention
solutes have increasingly been recognized to play a
pathophysiological role in the uremic syndrome. p-Cresol, a
representative of this group of molecules, has been shown to
be implicated in uremic immunodeficiency and endothelial
dysfunction, potentially linking its serum levels to mortality.
Thus far, however, no clinical information on this issue is
available. To determine the relationship between p-cresol
and all-cause mortality, 175 prevalent hemodialysis (HD)
patients were enrolled in a prospective study. At baseline,
serum levels of the water-soluble solutes urea, creatinine,
and phosphate, the middle molecule b2-microglobulin, total
and free concentrations of the protein-bound solute p-cresol,
and several risk factors for mortality were evaluated. During a
median follow-up of 34 months, 60 patients died. Baseline
comorbidity (Davies score) (hazard ratio (HR), 1.49; 95%
confidence interval (95% CI), 1.19–1.86), impaired nutritional
status (HR, 4.22; 95% CI, 2.15–8.29), time since initiation of
dialysis (HR, 0.98; 95% CI, 0.97–1.00), and higher free
concentrations of the protein-bound solute p-cresol (HR, 2.28;
95% CI, 1.12–4.64) were independently associated with
mortality (multivariate Cox proportional hazards analysis).
Our data suggest that free serum levels of p-cresol, a
representative of the protein-bound uremic retention solutes,
are associated with mortality in HD patients. These findings
may encourage nephrologists to widen their field of interest
beyond the scope of small water-soluble uremic solutes and
middle molecules.
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When in the 1960s dialysis strategies as a maintenance
therapy for stage 5 chronic kidney disease were introduced in
clinical practice, the quality of life and survival of patients
improved substantially. Efficiency of dialysis was estimated
based on the kinetics of small water-soluble uremic retention
solutes, notably urea nitrogen.1 The findings of early studies
were supportive for this approach, since they indicated
a benefit of higher removal of urea nitrogen with regard to
morbidity and mortality.2
However, despite less efficient removal of small water-
soluble molecules by peritoneal dialysis as compared to
hemodialysis (HD), peritoneal dialysis patients were seen to
have a similar clinical condition as their HD counterparts.3
This observation questioned the importance of small water-
soluble molecules in the uremic syndrome. It gave rise to the
middle-molecule hypothesis,4 which suggests a pathophysio-
logical role for molecules with a higher molecular mass than
urea nitrogen in the development of the uremic syndrome.
Nevertheless, since it was impossible at that time to identify
these solutes, urea kinetic modeling became established as the
most valuable tool for assessment of dialysis adequacy.5
During the previous decades, the middle-molecule hypoth-
esis has regained interest by the characterization of several
representatives of this molecular mass class.6 Moreover,
recent research work has directed attention towards another
distinct group of uremic retention molecules: the protein-
bound solutes.7 Although most of them have a low molecular
mass, binding to serum proteins hampers their dialytic
removal. p-Cresol, a 108-Da colonic fermentation metabolite
of the amino acid tyrosine, is considered a prototype of this
group of uremic solutes. The protein binding of this molecule
was shown to be about 90% in stage 5 chronic kidney disease
patients.8 Among different in vitro studies, several have
suggested that p-cresol plays a role in the immunodeficiency
of uremia.9–11 Recently, a link between p-cresol and endo-
thelial dysfunction has been demonstrated.12,13 In spite of
these in vitro findings, only few data on the clinical
importance of the solute have been reported to date. Free
serum concentrations of p-cresol were shown to be higher
in HD patients hospitalized for infectious disease.14
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Furthermore, a positive relationship was found between total
serum levels of p-cresol and a uremic symptom score in
patients treated with peritoneal dialysis, whereas a correlation
with small water-soluble solutes and the middle molecule
b2-microglobulin was absent.
15 Based on the above-men-
tioned in vitro relationships of p-cresol with immune and
endothelial cell dysfunction, it is tempting to speculate
on this solute as a contributor to the high mortality of
dialysis patients. Thus far, however, no information on this
issue is available. The principal aim of this prospective
observational cohort study was to investigate the association
between total and free serum levels of p-cresol and survival in
prevalent HD patients.
RESULTS
Baseline characteristics of the patients are shown in the first
column of Table 1. After a follow-up of 30.170.4 months
(median 34.0, minimum–maximum 22.0–34.0), 60 of the 175
patients (34%) had died. Causes of death were cardiovascular
in 30, infectious in 12, and malignancy in four. Of the
remaining 14, one patient died due to a hemorrhagic
complication after abdominal surgery and one of noninfec-
tious respiratory insufficiency due to end-stage pulmonary
emphysema. In six patients cause of death was defined as
cachexia without evidence for malignancy or infection. Six
patients died at home from a nonspecified cause. In all, 28
patients were transplanted and six were transferred to
another dialysis centre during follow-up.
Table 2 shows the relative risks of death estimated by
univariate Cox proportional hazards analysis. Age at baseline,
serum albumin, C-reactive protein (CRP), creatinine,
phosphate, residual renal function, impaired nutritional
status according to Subjective Global Assessment (SGA),
Malnutrition–Inflammation Score (MIS), Davies score and
grade, atherosclerotic disease, and diabetes were significantly
associated with mortality. Total serum levels of p-cresol were
not associated with outcome. Free concentrations of the
solute, however, were significantly related to mortality.
Figure 1 shows the Kaplan–Meier survival curves of patients
with high (X1.97 mg/l, n¼ 88) and with low (o1.97 mg/l,
n¼ 87) free serum levels of p-cresol. The survival difference
between the two groups was statistically significant (log-rank
P-value 0.041).
The second and third columns of Table 1 show baseline
data of patients with high and low free concentrations of
p-cresol separately. As compared to the latter, those with high
levels had lower serum albumin, higher total p-cresol
concentrations, and lower renal Kt/V of urea nitrogen
(rKt/V). Moreover, they were older, had been treated with
dialysis for a longer time, and were more likely to be treated
Table 1 | Baseline characteristics of the patients
Variable All (n=175) Free p-cresol X1.97 mg/l (n=88) Free p-cresol o1.97 mg/l (n=87) P
Age (years) 64.771.1 (67, 26–89) 68.271.6 (72, 26–89) 61.271.6 (62, 31–86) 0.001
Sex (male/female) 108/67 50/38 58/29 0.180
Time since dialysis initiation (months) 29.872.5 (18.1, 2.3–158.1) 37.874.2 (24.6, 2.3–158.1) 21.772.2 (14.9, 2.5–128.0) 0.021
Treatment modality (HD/HDF) 107/68 63/25 44/43 0.004
Bicarbonate (mEq/l) 22.970.2 (22.6, 17.2–40.0) 22.770.2 (22.5, 17.7–26.7) 23.170.3 (22.8, 17.2–40.0) 0.642
Hemoglobin (g/dl) 11.670.1 (11.6, 7.3–15.0) 11.570.1 (11.5, 7.3–14.8) 11.670.2 (11.8, 8.0–15.0) 0.285
Albumin (g/dl) 3.6470.03 (3.66, 2.69–4.48) 3.5870.03 (3.61, 4.37–4.48) 3.7070.04 (3.72, 2.85–4.48) 0.017
CRP (mg/l) 21.872.6 (8.0, 3.0–211.8) 20.873.4 (8.3, 3.0–211.8) 22.873.9 (7.5, 3.0–184.0) 0.564
Urea (mg/dl) 142.473.0 (138, 34–266) 155.974.4 (152, 63–266) 128.873.6 (129, 34–244) o0.0001
Creatinine (mg/dl) 8.670.2 (8.6, 2.5–14.5) 8.970.3 (8.9, 2.8–14.0) 8.370.3 (8.2, 2.5–14.5) 0.097
Phosphate (mg/dl) 4.870.1 (4.6, 1.6–9.3) 4.770.2 (4.6, 1.9–9.3) 5.070.2 (4.8, 1.6–9.3) 0.309
b2-Microglobulin (mg/l) 27.770.8 (26.5, 8.2–84.9) 30.470.9 (29.5, 15.0–63.1) 24.971.1 (23.6, 8.2–84.9) o0.0001
Total p-cresol (mg/l) 19.070.9 (18.9, 0.3–60.5) 26.571.0 (23.4, 12.3–60.5) 11.470.8 (13.4, 0.3–25.0) o0.0001
Free p-cresol (mg/l) 2.5970.17 (1.97, 0.30–12.74) 4.1270.24 (3.39, 1.97–12.74) 1.0670.05 (1.08, 0.30–1.94) o0.0001
% free p-cresol of total 13.0370.44 (11.61, 4.61–39.59) 15.4970.58 (14.25, 7.61–39.59) 9.7070.42 (8.89, 4.61–23.58) o0.0001
spKt/V 1.6470.04 (1.50, 0.04–3.80) 1.6670.06 (1.56, 0.04–3.62) 1.6170.05 (1.49, 0.76–3.80) 0.276
rKt/V 0.0670.01 (0, 0–0.79) 0.0470.01 (0, 0–0.79) 0.0770.01 (0.02, 0–0.43) 0.019
nPCR (g/kg/day) 0.9370.02 (0.92, 0.15–1.71) 1.0270.03 (1.03, 0.15–1.71) 0.8570.02 (0.83, 0.45–1.51) o0.0001
Body weight (kg) 66.671.1 (64.6, 42.5–112.0) 65.971.6 (63.2, 45.4–112.0) 67.271.5 (66.1, 42.5–106.5) 0.336
BMI (kg/m2) 23.970.4 (23.0, 16.0–48.6) 24.270.6 (23.1, 16.9–48.6) 23.770.4 (22.7, 16.0–35.2) 0.929
Fat mass (kg) 18.470.9 (15.3, 3.4–56.3) 19.171.4 (15.4, 3.4–56.3) 17.471.2 (15.1, 5.8–40.0) 0.631
FFM (kg) 48.670.9 (49.3, 30.3–71.1) 47.971.2 (49.0, 32.9–64.9) 49.571.4 (51.1, 30.3–71.1) 0.421
MAMC (cm) 23.470.3 (23.2, 15.0–31.4) 23.370.4 (22.9, 17.0–31.4) 23.670.5 (23.8, 15.0–30.8) 0.362
SGA (% impaired nutritional status) 32.9% 44.0% 21.1% 0.003
MIS 6.1770.33 (5, 0–22) 6.9570.47 (6, 0–22) 5.3770.45 (4, 0–22) 0.011
Davies score 1.8470.11 (2, 0–6) 1.9570.14 (2, 0–6) 1.7270.16 (2, 0–5) 0.246
Davies grade (low/medium/high) 38/81/56 13/47/28 25/34/28 0.053
Atherosclerotic disease (%) 46.6% 54.0% 39.0% 0.048
Diabetes (%) 29.7% 33.0% 26.4% 0.346
HD, hemodialysis; HDF, hemodiafiltration; CRP, C-reactive protein; spKt/V, single-pool Kt/V of urea nitrogen; rKt/V, renal Kt/V of urea nitrogen; nPCR, normalized protein
catabolic rate; BMI, body mass index; FFM, fat-free mass; MAMC, mid-arm muscle circumference; SGA, Subjective Global Assessment; MIS, Malnutrition–Inflammation Score.
Data are expressed as mean7s.e.m. (median, minimum–maximum). Differences between patients with high (X1.97 mg/l) and low (o1.97 mg/l) free p-cresol were evaluated
using Mann–Whitney U-test or the w2 test for association where appropriate. Two-sided P-values are indicated in the last column.
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with HD instead of hemodiafiltration (HDF). While their
daily protein intake per kg body weight (normalized protein
catabolic rate) was higher, they showed more signs of
impaired nutritional status based on SGA and had a higher
MIS. Finally, a significantly larger proportion of patients with
high free levels of p-cresol at baseline had atherosclerotic
disease as compared to those with low levels. To identify
independent determinants of free p-cresol concentrations, a
multivariate linear regression analysis was performed as
outlined in Materials and Methods. Since MIS is mathema-
tically dependent on other relevant variables (albumin and
SGA), it was not introduced into the model. Also, Davies
score, Davies grade, diabetes, and atherosclerotic disease are
by definition covarying variables. For that reason, only
Davies score was used. In the final regression model, the
following variables were retained as independent predictors
of the free serum level of p-cresol: serum albumin
(Po0.0001), age (P¼ 0.013), total p-cresol (Po0.0001),
and impaired nutritional status based on SGA (P¼ 0.005).
The respective regression coefficients allowed formulating the
following equation, which explained 77.6% (adjusted R2) of
the variability of free p-cresol (mg/l): 4.92–1.30 (serum
albumin (g/dl))–0.02 (age (years))þ 0.17 (total p-cresol
(mg/l))þ 0.60 (in case of impaired nutritional status
according to SGA).
Based on the findings of the univariate Cox proportional
hazards analyses (Table 2) and taking the variables related to
the free concentration of p-cresol into account (Table 1), the
following parameters were entered in the multivariate
survival analysis: age, sex, time since initiation of dialysis,
treatment modality, hemoglobin, albumin, CRP, urea,
creatinine, phosphate, b2-microglobulin, free p-cresol, rKt/
V, normalized protein catabolic rate, fat-free mass, mid-arm
muscle circumference, SGA, and Davies score. Free p-cresol
was entered as a binary variable (X1.97 mg/l or o1.97 mg/l)
(Model A) or as a continuous variable (Model B). The propor-
tionality assumption was fulfilled for all of the variables
studied (proportionality test overall P-value¼ 0.536). In
Table 3 the final results of Models A and B are given. Time
since initiation of dialysis, Davies score, and impaired
nutritional status based on SGA were consistently retained
as independent factors influencing survival. Depending on
the definition of the variable, the free serum level of p-cresol
remained in the final model (Model A) or lost significance in
the final step of the initial screening (Model B).
DISCUSSION
The results of this prospective observational cohort study
suggest that, besides other well-known predictors of survival,
the free serum level of the protein-bound uremic retention
solute p-cresol is related to mortality in patients treated with
dialysis. Several in vitro data have suggested a pathophysio-
logical role of the solute in some important aspects of the
uremic syndrome. p-Cresol depressed the respiratory burst
Table 2 | Univariate Cox proportional hazards analysis for
association of baseline variables with all-cause mortality
(n=175)
Variable Unit of increase HR P
Age 1 year 1.04 (1.02–1.07) 0.0002
Sex Male vs female 0.65 (0.39–1.08) 0.096
Time since dialysis
initiation
1 month 1.00 (0.99–1.01) 0.717
Treatment modality HDF vs HD 0.58 (0.33–1.04) 0.065
Bicarbonate 1 mEq/l 0.98 (0.89–1.08) 0.685
Hemoglobin 1 g/dl 0.86 (0.72–1.04) 0.123
Albumin 0.1 g/dl 0.89 (0.82–0.96) 0.004
o3.5 g/dl vs X3.5 g/dl 1.76 (1.06–2.94) 0.030
CRP 10 mg/l 1.07 (1.01–1.13) 0.024
X8.0 mg/l vs o8.0 mg/l 2.00 (1.17–3.40) 0.011
Urea 1 mg/dl 1.00 (0.99–1.01) 0.667
Creatinine 1 mg/dl 0.79 (0.70–0.88) o0.0001
Phosphate 1 mg/dl 0.83 (0.70–0.99) 0.036
b2-microglobulin 10 mg/l 1.05 (0.83–1.33) 0.678
Total p-cresol 10 mg/l 1.17 (0.95–1.46) 0.142
Free p-cresol 1 mg/l 1.10 (1.00–1.21) 0.058
X1.97 vs o1.97 mg/l 1.73 (1.02–2.94) 0.043
% Free p-cresol
of total
1% 1.03 (0.98–1.07) 0.270
spKt/V 1 unit 0.71 (0.38–1.33) 0.287
rKt/V 1 unit 0.01 (0.00–1.19) 0.060
Present vs absent 0.51 (0.30–0.88) 0.016
nPCR 1 g/kg/day 0.84 (0.28–2.58) 0.762
Body weight 1 kg 1.00 (0.98–1.02) 0.852
BMI 1 kg/m2 1.02 (0.96–1.08) 0.465
Fat mass 1 kg 1.02 (0.99–1.05) 0.287
FFM 1 kg 0.98 (0.94–1.01) 0.127
MAMC 1 cm 0.90 (0.81–1.01) 0.068
SGA ‘Impaired’ vs ‘normal’ 3.29 (1.87–5.80) o0.0001
MIS 1 unit 1.11 (1.05–1.19) 0.001
Davies score 1 unit 1.63 (1.36–1.96) o0.0001
Davies grade 1 grade 2.65 (1.74–4.04) o0.0001
Atherosclerotic
disease
Present vs absent 2.19 (1.29–3.74) 0.004
Diabetes Present vs absent 2.37 (1.43–3.94) 0.001
HD, hemodialysis; HDF, hemodiafiltration; CRP, C-reactive protein; spKt/V, single
pool Kt/V of urea nitrogen; rKt/V, renal Kt/V of urea nitrogen; nPCR, normalized
protein catabolic rate; BMI, body mass index; FFM, fat-free mass; MAMC, mid-arm
muscle circumference; SGA, Subjective Global Assessment; MIS, Malnutrition–In-
flammation Score.
Relative risks of death for each variable are given as HR (95% CI) and P-value for the
univariate Cox proportional hazards analysis.
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Figure 1 | Kaplan–Meier survival curves of patients with high free
serum levels of p-cresol (X1.97 mg/l, n¼ 88) and patients with
low free serum levels of p-cresol (o1.97 mg/l, n¼ 87). The P-value
of the log-rank test is indicated in the figure (B, censored value).
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reactivity of granulocytes and monocytes at concentrations
encountered in stage 5 chronic kidney disease patients.9 Later
it was shown that the solute inhibits the synthesis of platelet-
activating factor, another aspect of leukocyte function.10
Further evidence for a role of p-cresol in the immunodefi-
ciency of uremia was provided by the recent finding of its
inhibitory effect on cytokine-induced expression of the endo-
thelial adhesion molecules intercellular adhesion molecule-1
and vascular cellular adhesion molecule-1.11 Endothelial
dysfunction is another characteristic of the uremic syn-
drome.16 It is considered to be an important contributor to
the burden of cardiovascular atherosclerotic complications in
renal disease patients. That p-cresol might be implicated
in this disorder was suggested recently by two in vitro
studies that described an inhibition of the regenerative
properties and an increase in the permeability of endothelial
cells by uremic concentrations of the solute.12,13 In
accordance with the data linking p-cresol to immunodefi-
ciency, a study by De Smet et al.14 described higher free
serum levels of the solute in a group of HD patients
hospitalized for infectious disease as compared to those
hospitalized for other reasons. From the absence of a
difference in total p-cresol between the two groups and
results of in vitro experiments described in the same paper,
the authors concluded that, similar to protein-bound drugs,
the free, rather than the total, concentration of p-cresol is
responsible for its biological activities. Our findings are in
agreement with that thesis. Indeed, although survival of
patients with total serum levels of p-cresol X18.9 mg/l
was worse than in those with lower levels (50 vs 66%, log-
rank P-value¼ 0.456), only the free serum concentrations of
the solute conferred significantly to outcome.
Instead of attributing our findings to the sole influence of
p-cresol, it seems more reasonable to consider the molecule
as a representative of the group of protein-bound retention
solutes. Indeed, also other members of this group have been
found to be associated with immune dysfunction, endothelial
cell dysfunction, and, closely related to the latter, oxidative
stress. Like p-cresol, indoxyl sulfate was found to inhibit
endothelial proliferation and wound repair.12 Moreover, the
molecule was shown to induce free radical production by
renal tubular cells and activate nuclear factor kB, a central
mediator of atherosclerosis.17 Recently, another protein-
bound uremic compound, phenylacetic acid, was identified
to have an inhibitory impact on inducible nitric oxide
synthase, an enzyme with a protective potential on
endothelial function.18
In accordance with earlier observations, our data confirm
that the relative risk of death in dialysis patients increases
with higher age, the presence of atherosclerotic disease,
diabetes, and higher overall comorbidity (Table 2).19 Residual
renal function seems to be a protective factor. Although the
latter has been shown before in several studies including
peritoneal dialysis patients, only few other studies with HD
patients report on this issue.20,21 Finally, parameters reflect-
ing impaired nutritional status and/or inflammation, such as
low serum albumin, low creatinine, high CRP, unfavorable
SGA, and high MIS, are strong predictors of mortality. These
observations are in agreement with literature data reporting
on the association between malnutrition, inflammation,
atherosclerosis, and mortality in renal disease patients.22 In
each of the multivariate models, comorbidity and nutritional
status were retained as independent factors influencing
survival (Table 3). Depending on the definition of the
variable, the free serum level of p-cresol remained in the
model or lost its significance in one of the final elimination
steps. This discrepancy between Models A and B may seem
confusing at first sight. In our opinion, however, it reflects
the complex interplay between (free) p-cresol and other
important baseline variables as far as their relationship with
outcome is concerned. As can be appreciated from Table 1
and from the multivariate regression analysis, baseline free
serum concentrations of p-cresol were indeed significantly
related to age, serum albumin, impaired nutritional status
according to SGA, MIS, and the presence of atherosclerotic
disease, all associated with mortality themselves. The present
study, however, does not allow to define the exact role of
(free) p-cresol within this group of variables and further
investigation will be needed to resolve this intriguing
question. Nevertheless, whatever the strength and causality
of the relationship between p-cresol and the other variables, it
is clear from our data that a high free serum level of the
solute (or related solutes) constitutes an additive risk factor
for mortality in a dialysis population. Furthermore, it should
be noted that only higher free levels of p-cresol were related
to mortality, whereas no such relationship was seen for any of
the other uremic retention molecules studied. This is of
particular interest in view of the results of the recent
hemodialysis (HEMO) and adequacy of dialysis Mexico
(ADEMEX) studies.19,23 These randomized trials failed to
show an improvement of patient outcome by increasing the
removal of low-molecular-mass water-soluble solutes and
even middle molecules above current standards. Besides
Table 3 | Multivariate Cox proportional hazards analysis
of baseline variables associated with all-cause mortality
(n=175)a
Variable Unit of increase HR (95% CI) P
Model A (‘free p-cresol’ entered as a binary variable)
Months on dialysis 1 month 0.98 (0.97–1.00] 0.005
Free p-cresol high vs lowb 2.28 (1.12–4.64) 0.023
SGA ‘impaired’ vs ‘normal’ 4.22 (2.15–8.29) o0.0001
Davies score 1 unit 1.49 (1.19–1.86) 0.001
Model B (‘free p-cresol’ entered as a continuous variable)
Age 1 year 1.03 (1.00–1.06) 0.047
Months on dialysis 1 month 0.98 (0.97–1.00) 0.007
SGA ‘impaired’ vs ‘normal’ 4.42 (2.25–8.71) o0.0001
Davies score 1 unit 1.45 (1.17–1.80) 0.001
SGA, Subjective Global Assessment.
Relative risk of death for each variable is given as HR (95% CI) and P-value for Cox
proportional hazards analysis.
aSee Materials and methods for detailed description of the statistical methods used.
b‘High’ means X1.97 mg/l, ‘low’ means o1.97 mg/l.
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several other hypotheses that have been put forward to
explain these findings,24,25 one should consider the limited
removal of protein-bound solutes by the dialysis strategies
evaluated in these trials. In view of the results of the present
study, there seems to be an incentive to search for strategies
that improve protein-bound solute removal and to investi-
gate their impact on patient outcome.
Finally, from a methodological point of view, one might
question the validity of survival statistics based on a single
baseline measurement of the p-cresol level. Indeed, consider-
able bias could be expected if intraindividual variability
over time were large. However, by measurement of three
pre-dialysis p-cresol serum levels in seven patients (a) during
1 week and (b) 12 weeks apart, the pre-dialysis p-cresol
was found to be acceptably stable (coefficient of variation
(a) 12.172.3% (median 10.5, minimum–maximum 2.0–19.4);
(b) 12.672.3% (median 9.6, minimum–maximum 6.1–21.3)).
Another issue worth addressing is the fact that the median free
p-cresol concentrations used to divide the study population in
a high and low free p-cresol cohort should not be regarded as a
clinically applicable cutoff value. We used this approach to
enable reliable statistics on groups of equal and sufficient size.
Again, larger trials with longer follow-up times will help to
define relevant cutoff points that can be used in clinical
algorithms.
In conclusion, our data suggest for the first time that free
serum levels of the protein-bound uremic retention solute
p-cresol are associated with mortality in patients treated
with HD. Besides the molecule’s own toxic effects, this
finding probably reflects the toxicity of an entire group of
physicochemically related retention solutes. Taking the results
of the recent HEMO and ADEMEX studies into considera-
tion, we believe that these findings may encourage scientists
and clinicians to widen their field of interest beyond the
scope of the small water-soluble uremic solutes and middle
molecules.19,23
MATERIALS AND METHODS
Patients
In total, 175 patients with stage 5 chronic kidney disease (108 males,
67 females) who had undergone regular dialysis treatment for at
least 2 months (29.872.5 months (median 18.1, minimum–max-
imum 2.3–158.1)) in two Belgian HD centers (University Hospital,
Leuven and Virga Jesse Hospital, Hasselt) were enrolled at two
inclusion dates (January 1, 2002 and January 1, 2003). Causes of
renal disease were diabetic nephropathy (n¼ 34), polycystic kidney
disease (n¼ 18), glomerular disease (n¼ 40), tubulointerstitial
disease (n¼ 25), vascular disease (n¼ 8), and unknown etiologies
(n¼ 50). At inclusion, none of the patients had malignant disease,
which could be expected to influence prognosis. All patients were
being treated three times 4 h a week with HD or hemodiafiltration
(post-dilution mode with 20 l of substitution fluid) using synthetic
polysulfone or polyamide dialysis membranes with a surface area of
1.4–1.8 m2. Dialyzers were not reused. The dialysate and/or
substitution fluid contained 138.0 mEq/l sodium, 1.0–3.0 mEq/l
potassium, 1.22 mg/dl magnesium, 6.0 mg/dl calcium, 32.0 mEq/l
bicarbonate, 18.0 mg/dl acetate, and 100 mg/dl glucose. Purity of the
fluids was monitored according to internationally accepted guide-
lines.26 Dialysis efficiency was targeted based on single-pool Kt/V of
urea nitrogen according to the National Kidney Foundation-Kidney
Disease Outcomes Quality Initiative guidelines.5 Dry weight was
defined in every patient to achieve a normotensive edema-free state.
The study was performed according to the principles of the
Declaration of Helsinki Principles and was approved by the ethical
committees of the University Hospital, Leuven and the Virga Jesse
Hospital, Hasselt. Informed consent was obtained from all patients.
Procedures
Baseline evaluation. At inclusion, the following analyses were
performed on a blood sample taken immediately before the mid-
week dialysis treatment: bicarbonate (mEq/l), hemoglobin (g/dl),
albumin (g/dl), urea (mg/dl), creatinine (mg/dl), phosphate (mg/
dl), b2-microglobulin (mg/l), and total and free p-cresol (mg/l). As a
baseline measure of inflammation, the mean of all CRP (mg/l)
levels, measured from 45 days before to 45 days after the inclusion
date, was calculated.
Dialysis efficiency was evaluated according to the National
Kidney Foundation-Kidney Disease Outcomes Quality Initiative
guidelines.5 Single-pool Kt/V of urea nitrogen was calculated using
the second-generation logarithmic formula of Daugirdas.27 Residual
renal function was estimated from an interdialytic urine collection
and expressed as weekly rKt/V.
As a measure of daily protein intake, normalized protein
catabolic rate (g/kg/day) was calculated.28 Anthropometrical para-
meters measured were body weight (kg) and body mass index,
calculated from height and body weight (kg/m2). Furthermore, fat
mass, fat-free mass, and mid-arm muscle circumference were
calculated from skinfold measurements and mid-arm circumference
according to the appropriate formulas.29 All measurements were
performed by a skilled dietician within the first hour after the end
of the dialysis session, when the patient was considered to be at
dry weight.
Overall assessment of nutritional status was performed by SGA
according to Detsky et al. and was reported as ‘impaired nutritional
status’ (SGA scores B or C) or ‘normal nutritional status’ (SGA
score A).30 As a parameter reflecting both nutritional status and
inflammation, the MIS was calculated. This comprehensive scoring
system with a possible range from 0 to 30 combines components of
the SGA with three additional elements (serum albumin, total iron-
binding capacity, and body mass index).31
Based on a review of the medical records, comorbidity at baseline
was assessed using the method described by Davies et al.32 In brief,
seven categories of comorbid conditions were scored as ‘1’ (present)
or ‘0’ (absent). The total sum of scores was used to determine the
grade of comorbidity. Grade 0 (low risk) is a zero score, grade 1
(medium risk) is a score of 1–2 and grade 2 (high risk) a cumulative
score of X3. Patients scoring 1 in the categories ‘ischemic heart
disease’ and/or ‘peripheral vascular disease’ were considered to have
atherosclerotic disease. The presence or absence of diabetes was also
considered as a separate variable.
Biochemical analyses. Hemoglobin, total iron-binding
capacity, CRP, bicarbonate, creatinine, urea, phosphate, and
b2-microglobulin were measured using standard laboratory
techniques. The bromocresol green method was used for the
determination of albumin. Total p-cresol (i.e. combined free and
protein-bound fraction) was analyzed by the gas chromatography
mass spectrometry technology as described earlier.15,33 In summary,
after deproteinization (acid and heat), addition of the internal
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standard (2,6-dimethylphenol), and extraction (ethyl acetate), the
samples were transferred to the gas chromatography mass spectro-
metry (Trace GC-MS, Thermofinnigan, San Jose´, CA, USA) for
injection and separation on a column, followed by identification of
p-cresol by mass spectrometry. For the determination of free p-
cresol, serum was first ultrafiltered at room temperature with an
ultrafiltration membrane (Centrifree and MPS Micropartition UF
Devices, Amicon, Beverly, MA, USA) with a molecular cutoff of
30 000 Da, followed by the same sample preparation and gas
chromatography mass spectrometry analysis. Quantitative results
were obtained by the internal standard method and calculated
as concentrations (mg/l). The method has low intra- and inter-
assay variabilities (coefficient of variation 3.33 and 5.30%,
respectively). The detection limit for measurement of p-cresol is
0.15 mg/l and the limit of quantification is 0.30 mg/l. Values
below the limit of quantification were treated as 0.30 mg/l in the
statistical evaluation.
Follow-up and study end. Patients were followed up until
November 30, 2004. During follow-up, deaths were accurately
recorded and cause of death was specified. Causes of death were
categorized as cardiovascular, infectious, malignancy or other.
Statistical analysis
Data are expressed as mean7s.e.m. The median and range of each
variable are given between brackets. For some analyses, the total
group of patients was dichotomized based on the serum level of
albumin (o3.5 g/dl orX3.5 g/dl; HEMO study’s standard of care as
cutoff19), the free concentration of p-cresol (X1.97 mg/l or
o1.97 mg/l; median as cutoff), the serum level of CRP (X8.0 mg/
l or o8.0 mg/l; median as cutoff), residual renal function (present
(rKt/V40) or absent (rKt/V¼ 0)) or Davies score (X2 or o2;
median as cutoff). The baseline characteristics of patients with high
(X1.97 mg/l) and low (o1.97 mg/l) free p-cresol were compared
using the Mann–Whitney U-test. Categorical data were compared by
the w2 test for association. To identify independent determinants of
free concentrations of p-cresol, multivariate linear regression
analysis was performed, including all univariately associated
variables (Po0.2). After excluding colinearity, the best subset of
variables was selected by backward elimination on Po0.2. This
subset was then subjected to a final backward elimination procedure
on Po0.05. Inspection of residual plots assured that the a priori
assumptions for linear regression were justified.
Survival analysis was performed using two different statistical
approaches. First, the univariate Cox proportional hazards model
was used and the relative risk of death was expressed as a HR.
Second, the cumulative incidence of death during follow-up was
estimated by the Kaplan–Meier method, and the log-rank test was
used to compare the differences of variables affecting survival. In
each approach, data were censored at transplantation, transfer to
another dialysis center or at the end of follow-up (November 30,
2004). Variables that affected all-cause mortality and/or were
related to the free serum level of p-cresol (Po0.2) were included
in a multivariate Cox proportional hazards analysis. First, the
most relevant of them were selected by a backward elimination
on Po0.2. The selected subset of variables was then entered in
a backward elimination procedure on Po0.05 to define the best
model explaining the outcome variable. The proportionality
assumption was tested by using the ‘proportionality test’ statement
within the PHREG procedure and by inspection of
log(log(survival)) curves. HRs are given with their 95% CIs. P-
values less than 0.05 were considered significant. The SAS version
8.02 (SAS Institute, Cary, NC, USA) software program was used for
the statistical analysis.
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Note added in proof
Between acceptance and publication of the present paper, two
interesting studies on the molecule p-cresol have been published.
Indeed, Martinez et al. (Martinez AW, Recht NS, Hostetter TH et al.
Removal of p-cresol sulfate by hemodialysis. J Am Soc Nephrol 2005;
16: 3430–3436) and we (de Loor H, Bammens B, Evenepoel P et al. Gas
chromatographic-mass spectrometric analysis for measurement of
p-cresol and its conjugated metabolites in uremic and normal serum.
Clin Chem 2005; 51: 1535–1538), independently of each other, found
that p-cresol in human serum is almost entirely sulfated (p-
cresylsulfate). The fact that p-cresylsulfate in body fluids is detected
as p-cresol is due to the deconjugating effect of the analytical
methodology used.
Although the findings of the above-mentioned papers may ask for
a critical reappraisal of the in vitro toxicity data on p-cresol, they do
not abrogate clinical associations such as the ones described in the
present paper. Furthermore, in both studies the important protein
binding of p-cresylsulfate was confirmed, supporting its use as a
representative of the specific group of protein-bound uremic
retention solutes originating from colonic protein fermentation.
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